Chemometric Determination of Valsartan in The Presence of Its Carboxylic Acid-Induced Triiodide Ion Product by Spectrophotometric Method

Yıl 2022, Cilt: 2 Sayı: 4, 1 - 1, 14.10.2022

Fatma Demirkaya Miloğlu Elmas Polatdemir Yücel Kadıoğlu

Bu makale için 14 Ekim 2022 tarihinde bir düzeltme yayımlandı. https://dergipark.org.tr/tr/pub/paharmata/issue/73034/1236812

Öz

A new spectrophotometric method optimized with central composite design (CCD) for quantitative estimation of valsartan (VL) in pharmaceutical preparations was developed. The developed method is based on the oxidation of VL with potassium iodate (KIO3) to form a carboxylic acid derivative. In the presence of the -COOH group, iodide (KI) is oxidized by iodate, leading to the formation of a yellow-colored triiodide ion with an absorption maximum at 352 nm. The CCD, one of the chemometric methods were applied for the determination of the experimental conditions and then Kinetic studies were used for the stability period. The equilibration time was determined as 10 min. The volumes of 0.05 M KI and 0.003 M KIO3 were calculated as 1.92 mL (0.0192 M) and 2.96 mL (0.000177 M), respectively, and the temperature was measured as 27°C. The method was linear in the concentration range of 6-34 µg/mL (R2: 0.996). The LOD and LOQ were obtained as 0.81 and 2.46 µg/mL, respectively. The pharmaceutical dosage forms were analyzed with developed method, and the obtained results ranged from 98.3% to 102.9%. The developed method was a simple, rapid and inexpensive method for routine analysis of VL in pharmaceutical dosage form

Anahtar Kelimeler

Valsartan, Central composite design, UV-Vis Spectrophotometry

Kaynakça

• 1. De Wit C. Mechanobiology of arterial hypertension.Vascular Mechanobiology in Physiology and Disease. 2021; 277-98.
• 2. Omboni S, Volpe M. Angiotensin receptor blockers versus angiotensin converting enzyme inhibitors for the treatment of arterial hypertension and the role of olmesartan. Advances in Therapy. 2019;36(2):278-97.
• 3. Remuzzi A, Perico N, Remuzzi G. Pharmacological and clinical profile of valsartan. Drugs Today. 1998; 34(11):973-86.
• 4. Tatar S, Sağlık S. Comparison of UV-and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. Journal of Pharmaceutical and Biomedical Analysis. 2002; 30(2):371-75.
• 5. Stolarczyk M, Apola A, Maślanka A, Kwiecień A, Opoka W. Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures. Acta Pharmaceutica. 2017; 67(4), 463-78.
• 6. Jadhav ML, Girase MV, Tidme SK, Junagade MS. Development and validation of spectrophotometric methods for simultaneous estimation of Valsartan and Hydrochlorothiazide in tablet dosage form. International Journal of Spectroscopy. 2014; Article ID 873819, 1-6.
• 7. Makvana C, Sahoo S. Spectrophotometric method development and validation for simultaneous estimation of nebivolol hydrochloride and valsartan ın bulk and combined pharmaceutical dosage form ın release media. International Journal of Pharmaceutical Sciences and Drug Research.2019; 11(06):299-304.
• 8. Stolarczyk M, Maślanka A, Krzek J, Milczarek J. Application of derivative spectrophotometry for determination of enalapril, hydrochlorothiazide and walsartan in complex pharmaceutical preparations. Acta Poloniae Pharmaceutica. Drug Research. 2008; 65(3):275-81.
• 9. Darwish HW, Hassan SA, Salem MY, El-Zeany BA.Comparative study between derivative spectrophotometry and multivariate calibration as analytical tools applied for the simultaneous quantitation of Amlodipine, Valsartan and Hydrochlorothiazide. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2013;113:215-23.
• 10. Moustafa Abdallah O, Badawey AM. Determination of amlodipine and valsartan in binary mixture using derivative-ratio spectrophotometric, chemometric and high performance liquid chromatographic-UV methods. International Journal of Industrial Chemistry. 2011; 2(3):131-139.
• 11. Trivedi GS, Raj HA, Jain VC. First derivative spectroscopic method for simultaneous estimation of Pravstatin and Valsartan in synthetic mixture. Asian Journal of Pharmacy and Technology. 2015; 5(2): 83-90.
• 12. Ramachandran S, Mandal BK, Navalgund SG. Simultaneous spectrophotometric determination of valsartan and ezetimibe in pharmaceuticals. Tropical Journal of Pharmaceutical Research. 2011; 10(6): 809-15.
• 13. Peleshok K, Bondar B, Kryskiw L, Kucher T, Poliak O, Logoyda L. Non-extractive spectrophotometric determination of valsartan in pure form and in pharmaceutical products by ion-pair complex formation with bromophenol blue and methyl red. Pharmacia. 2021; 68(4):851-58.
• 14. Mallegowda S, Deepakumari H, Revanasiddappa H. Spectrophotometric Determination of Valsartan using p-Chloranilic Acid as π-Acceptor in Pure and in Dosage Forms. Journal of Applied Pharmaceutical Science. 2013; 3(1): 113-116.
• 15. Mazı C, Karaderi S, Arıöz F. Spectrophotometric Investigation of Metal Complexes with Valsartan. Journal of Chemistry and Materials Research. 2018; 10(5):61-8.
• 16. Demirkaya-Miloglu F, Polatdemir E, Senol O, Kadioglu Y. Design and Optimization of a Novel Spectrophotometric Method using Response Surface Methodology for the Determination of Losartan Potassium in Pharmaceuticals. Current Pharmaceutical Analysis. 2017; 13(6):552-58.
• 17. Rahman N, Siddiqui MR, Azmi SNH. Quantitative analysis of irbesartan in commercial dosage forms by kinetic spectrophotometry. Chemical and Pharmaceutical Bulletin. 2006; 54(5): 626-31.